Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accumulated Expenses (2024 - 2025)

Prelude Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 53.07% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $7.1 million, down 53.07%, while the annual FY2025 figure was $7.1 million, 53.07% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $7.1 million at Prelude Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.2 million in Q4 2024 and bottomed at $3.6 million in Q1 2024.